electroCore, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ECOR research report →
Companywww.electrocore.com
electroCore, Inc. , a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
- CEO
- Thomas J. Errico
- IPO
- 2018
- Employees
- 73
- HQ
- Rockaway, NJ, US
Price Chart
Valuation
- Market Cap
- $50.85M
- P/E
- -3.57
- P/S
- 1.46
- P/B
- -9.65
- EV/EBITDA
- -4.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 87.25%
- Op Margin
- -41.97%
- Net Margin
- -44.08%
- ROE
- 836.32%
- ROIC
- -379.10%
Growth & Income
- Revenue
- $32.03M · 27.20%
- Net Income
- $-13,966,000 · -17.50%
- EPS
- $-1.65 · -3.77%
- Op Income
- $-13,153,000
- FCF YoY
- -18.78%
Performance & Tape
- 52W High
- $8.64
- 52W Low
- $4.16
- 50D MA
- $6.38
- 200D MA
- $5.71
- Beta
- 0.68
- Avg Volume
- 65.12K
Get TickerSpark's AI analysis on ECOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 13, 26 | Fox Michael | other | 70,000 |
| Apr 10, 26 | Goldberger Daniel S | sell | 16,072 |
| Apr 13, 26 | Fox Michael | other | 0 |
| Apr 1, 26 | Lev Joshua S. | other | 45,000 |
| Mar 19, 26 | Errico Thomas J. | other | 19,252 |
| Mar 19, 26 | Errico Thomas J. | other | 22,803 |
| Mar 19, 26 | Errico Thomas J. | other | 22,803 |
| Mar 19, 26 | Errico Thomas J. | other | 19,252 |
| Jan 26, 26 | Lev Joshua S. | other | 25,000 |
| Jan 26, 26 | Lev Joshua S. | other | 2,889 |
Our ECOR Coverage
We haven't published any research on ECOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ECOR Report →